Although the scientific relevance in the aforementioned cardiovascular chance factor alterations by tirzepatide will be assessed in the planned cardiovascular consequence review SURPASS-CVOT ( "type":"scientific-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Assessment indica